1,827 results on '"10049 Institute of Pathology and Molecular Pathology"'
Search Results
2. Biallelic ELOC Inactivated Renal Cell Carcinoma: Molecular Features Supporting Classification as a Distinct Entity
- Author
-
Batavia, Aashil A, Rutishauser, Dorothea, Sobottka, Bettina, Schraml, Peter, Beerenwinkel, Niko, Moch, Holger, and University of Zurich
- Subjects
10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health - Published
- 2023
3. Third International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)
- Author
-
Elfgen, Constanze, Leo, Cornelia, Kubik-Huch, Rahel A, Muenst, Simone, Schmidt, Noemi, Quinn, Cecily, McNally, Sorcha, van Diest, Paul J, Mann, Ritse M, Bago-Horvath, Zsuzsanna, Bernathova, Maria, Regitnig, Peter, Fuchsjäger, Michael, Schwegler-Guggemos, Daniela, Maranta, Martina, Zehbe, Sabine, Tausch, Christoph, Güth, Uwe, Fallenberg, Eva Maria, Schrading, Simone, Kothari, Ashutosh, Sonnenschein, Martin, Kampmann, Gert, Kulka, Janina, Tille, Jean-Christoph, Körner, Meike, Decker, Thomas, Lax, Sigurd F., Daniaux, Martin, Varga, Zsuzsanna, et al, and University of Zurich
- Subjects
10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health - Published
- 2023
4. Breast lesions with myoepithelial phenotype
- Author
-
Foschini, Maria P, Nishimura, Rieko, Fabbri, Viscardo Paolo, Varga, Zsuzsanna, Kaya, Handan, Cserni, Gábor, and University of Zurich
- Subjects
Histology ,10049 Institute of Pathology and Molecular Pathology ,03.01. Általános orvostudomány ,610 Medicine & health ,General Medicine ,Pathology and Forensic Medicine - Abstract
Myoepithelial cells (MECs) constitute a continuous layer of cells surrounding the breast glands, localised between the epithelial cells (ECs) and the basal membrane. MECs play important roles in normal mammary gland as they produce basal membrane and stimulate secretion. During neoplastic transformation, MECs act as a barrier preventing stromal invasion. MECs themselves can undergo a great variety of changes, ranging from hyperplastic to metaplastic, to neoplastic, and giving rise to a wide spectrum of morphological pictures sometimes difficult to interpret on routine diagnoses. Several benign and malignant breast tumours can present features of MECs differentiation. As these latter tumours are quite infrequent, the purpose of the present study is to offer a review of the morphological spectrum of MECs lesions, with correlations to prognosis.
- Published
- 2022
5. Incidence of new onset glomerulonephritis after SARS-CoV-2 mRNA vaccination is not increased
- Author
-
Diebold, Matthias, Locher, Eleonore, Boide, Philipp, Enzler-Tschudy, Annette, Faivre, Anna, Fischer, Ingeborg, Helmchen, Birgit, Hopfer, Helmut, Kim, Min Jeong, Moll, Solange, Nanchen, Giliane, Rotman, Samuel, Saganas, Charalampos, Seeger, Harald, Kistler, Andreas D, University of Zurich, and Kistler, Andreas D
- Subjects
Adult ,COVID-19 Vaccines ,2727 Nephrology ,SARS-CoV-2 ,Incidence ,Vaccination ,COVID-19 ,Bayes Theorem ,610 Medicine & health ,Humans ,Retrospective Studies ,COVID-19 Vaccines/adverse effects ,COVID-19/epidemiology ,COVID-19/prevention & control ,Glomerulonephritis/epidemiology ,Glomerulonephritis/etiology ,Vaccination/adverse effects ,RNA, Messenger ,COVID vaccine ,IgA nephropathy ,SARS-CoV-2 vaccination ,glomerulonephritis ,membranous nephropathy ,minimal change disease ,Glomerulonephritis ,Nephrology ,10049 Institute of Pathology and Molecular Pathology ,10035 Clinic for Nephrology - Abstract
Numerous cases of glomerulonephritis manifesting shortly after SARS-CoV-2 vaccination have been reported, but causality remains unproven. Here, we studied the association between mRNA-based SARS-CoV-2 vaccination and new-onset glomerulonephritis using a nationwide retrospective cohort and a case-cohort design. Data from all Swiss pathology institutes processing native kidney biopsies served to calculate incidence of IgA nephropathy, pauci-immune necrotizing glomerulonephritis, minimal change disease, and membranous nephropathy in the adult Swiss population. The observed incidence during the vaccination campaign (January to August 2021) was not different from the expected incidence calculated using a Bayesian model based on the years 2015 to 2019 (incidence rate ratio 0.86, 95% credible interval 0.73-1.02) and did not cross the upper boundary of the 95% credible interval for any month. Among 111 patients 18 years and older with newly diagnosed glomerulonephritis between January and August 2021, 38.7% had received at least one vaccine dose before biopsy, compared to 39.5% of the general Swiss population matched for age and calendar-time. The estimated risk ratio for the development of new-onset biopsy-proven glomerulonephritis was not significant at 0.97 (95% confidence interval 0.66-1.42) in vaccinated vs. unvaccinated individuals. Patients with glomerulonephritis manifesting within four weeks after vaccination did not differ clinically from those manifesting temporally unrelated to vaccination. Thus, vaccination against SARS-CoV-2 was not associated with new-onset glomerulonephritis in these two complementary studies with most temporal associations between SARS-CoV-2 vaccination and glomerulonephritis likely coincidental.
- Published
- 2022
6. Molecular and immunophenotypic characterization of SMARCB1 (INI1) - deficient intrathoracic Neoplasms
- Author
-
Martina Haberecker, Marco Matteo Bühler, Alicia Pliego Mendieta, Roman Guggenberger, Fabian Arnold, Eva Markert, Markus Rechsteiner, Martin Zoche, Christian Britschgi, Chantal Pauli, University of Zurich, and Pauli, Chantal
- Subjects
DNA Helicases ,Nuclear Proteins ,Sarcoma ,610 Medicine & health ,SMARCB1 Protein ,Chromatin Assembly and Disassembly ,Immunohistochemistry ,Pathology and Forensic Medicine ,2734 Pathology and Forensic Medicine ,10049 Institute of Pathology and Molecular Pathology ,10032 Clinic for Oncology and Hematology ,Biomarkers, Tumor ,Humans ,Retrospective Studies ,Transcription Factors - Abstract
The switch/sucrose-non-fermenting (SWI/SNF) complex is an ATP-dependent chromatin remodeling complex that plays important roles in DNA repair, transcription and cell differentiation. This complex consists of multiple subunits and is of particular interest in thoracic malignancies due to frequent subunit alteration of SMARCA4 (BRG1). Much less is known about SMARCB1 (INI1) deficient intrathoracic neoplasms, which are rare, often misclassified and understudied. In a retrospective analysis of 1479 intrathoracic malignant neoplasms using immunohistochemistry for INI1 (SMARCB1) on tissue micro arrays (TMA) and a search through our hospital sarcoma database, we identified in total nine intrathoracic, INI1 deficient cases (n = 9). We characterized these cases further by additional immunohistochemistry, broad targeted genomic analysis, methylation profiling and correlated them with clinical and radiological data. This showed that genomic SMARCB1 together with tumor suppressor alterations drive tumorigenesis in some of these cases, rather than epigenetic changes such as DNA methylation. A proper diagnostic classification, however, remains challenging. Intrathoracic tumors with loss or alteration of SMARCB1 (INI1) are highly aggressive and remain often underdiagnosed due to their rarity, which leads to false diagnostic interpretations. A better understanding of these tumors and proper diagnosis is important for better patient care as clinical trials and more targeted therapeutic options are emerging.
- Published
- 2022
7. Lymphoid aggregates in bone marrow: a diagnostic pitfall
- Author
-
Maccio, Umberto, Rets, Anton V, University of Zurich, and Rets, Anton V
- Subjects
Diagnosis, Differential ,2734 Pathology and Forensic Medicine ,Bone Marrow ,Biopsy ,10049 Institute of Pathology and Molecular Pathology ,Humans ,610 Medicine & health ,General Medicine ,Immunohistochemistry ,Pathology and Forensic Medicine - Abstract
Lymphoid aggregates in bone marrow specimens are a relatively frequent finding that may pose a diagnostic challenge for a pathologist. The distinction between reactive and neoplastic aggregates has significant clinical relevance. Although many testing modalities such as immunohistochemistry, flow cytometry and molecular studies are currently available in clinical laboratories, the appropriate utilisation of these modalities and the awareness of their potential pitfalls are important. When a neoplastic process is ruled out, the significance of benign lymphoid aggregates in bone marrow is often unclear, as they may be associated with a broad spectrum of conditions including infections, autoimmune disorders, medications, or may even be idiopathic.This review focuses on evidence-based criteria that can aid in making the distinction between benign and malignant lymphoid aggregates and discusses the advantages, disadvantages and limits of ancillary tests used for this purpose. Finally, the most common aetiologies of benign lymphoid aggregates and their associations with specific diseases are discussed.
- Published
- 2022
8. Assessment of hepatic fibrosis and inflammation with look-locker T1 mapping and magnetic resonance elastography with histopathology as reference standard
- Author
-
von Ulmenstein, Sophie, Bogdanovic, Sanja, Honcharova-Biletska, Hanna, Blümel, Sena, Deibel, Ansgar R, Segna, Daniel, Jüngst, Christoph, Weber, Achim, Kuntzen, Thomas, Gubler, Christoph, Reiner, Cäcilia S, University of Zurich, and Reiner, Cäcilia S
- Subjects
Inflammation ,Liver Cirrhosis ,2748 Urology ,Radiological and Ultrasound Technology ,10042 Clinic for Diagnostic and Interventional Radiology ,Urology ,Gastroenterology ,610 Medicine & health ,Reference Standards ,Fibrosis ,Magnetic Resonance Imaging ,10219 Clinic for Gastroenterology and Hepatology ,Liver ,10049 Institute of Pathology and Molecular Pathology ,Elasticity Imaging Techniques ,Humans ,2741 Radiology, Nuclear Medicine and Imaging ,2715 Gastroenterology ,Radiology, Nuclear Medicine and imaging ,3614 Radiological and Ultrasound Technology - Abstract
Purpose To compare the diagnostic performance of T1 mapping and MR elastography (MRE) for staging of hepatic fibrosis and grading inflammation with histopathology as standard of reference. Methods 68 patients with various liver diseases undergoing liver biopsy for suspected fibrosis or with an established diagnosis of cirrhosis prospectively underwent look-locker inversion recovery T1 mapping and MRE. T1 relaxation time and liver stiffness (LS) were measured by two readers. Hepatic fibrosis and inflammation were histopathologically staged according to a standardized fibrosis (F0–F4) and inflammation (A0–A2) score. For statistical analysis, independent t test, and Mann–Whitney U test and ROC analysis were performed, the latter to determine the performance of T1 mapping and MRE for fibrosis staging and inflammation grading, as compared to histopathology. Results Histopathological analysis diagnosed 9 patients with F0 (13.2%), 21 with F1 (30.9%), 11 with F2 (16.2%), 10 with F3 (14.7%), and 17 with F4 (25.0%). Both T1 mapping and MRE showed significantly higher values for patients with significant fibrosis (F0-1 vs. F2-4; T1 mapping p p p p p = 0.01). T1 mapping showed a tendency toward lower diagnostic performance without statistical significance for significant fibrosis (F2-4) (AUC 0.79 vs. 0.91, p = 0.06) and with a significant difference compared to MRE for severe fibrosis (F3-4) (AUC 0.79 vs. 0.94, p = 0.03). For both T1 mapping and MRE, diagnostic performance for diagnosing hepatic inflammation (A1-2) was low (AUC 0.72 vs. 0.71, respectively). Conclusion T1 mapping is able to diagnose hepatic fibrosis, however, with a tendency toward lower diagnostic performance compared to MRE and thus may be used as an alternative to MRE for diagnosing hepatic fibrosis, whenever MRE is not available or likely to fail due to intrinsic factors of the patient. Both T1 mapping and MRE are probably not sufficient as standalone methods to diagnose hepatic inflammation with relatively low diagnostic accuracy.
- Published
- 2022
9. Bone marrow haematopoiesis in patients with COVID-19
- Author
-
Marques-Maggio, Ewerton, Maccio, Umberto, Marx, Alexandra, Galli, Serena, Schwab, Nathalie, Frank, Angela, Hamelin, Baptiste, Varga, Zsuzsanna, Nombela-Arrieta, César, Mertz, Kirsten D, Theocharides, Alexandre Pa, Koelzer, Viktor H, and University of Zurich
- Subjects
10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health - Published
- 2023
10. Histopathological Analysis of Nodal Disease After Chemoradiation Reveals Viable Tumor Cells as the most Important Prognostic Factor in Head and Neck Squamous Cell Carcinoma
- Author
-
Golliez, Aline, Morand, Grégoire B, Broglie, Martina A, Balermpas, Panagiotis, Rupp, Niels J, and University of Zurich
- Subjects
Oncology ,Otorhinolaryngology ,10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health ,10045 Clinic for Otorhinolaryngology ,10044 Clinic for Radiation Oncology ,Pathology and Forensic Medicine - Abstract
Background In head and neck squamous cell carcinoma (HNSCC), salvage neck dissection (ND) is required after primary chemoradiation in case of residual nodal disease. Upon histopathological examination, viability of tumor cells is assessed but little is known about other prognostic histopathological features. In particular, the presence of swirled keratin debris and its prognostic value is controversial. The aim of this study is to examine histopathological parameters in ND specimens and correlate them with patient outcome to determine the relevant parameters for histopathological reporting. Materials and Methods Salvage ND specimen from a cohort of n = 75 HNSCC (oropharynx, larynx, hypopharynx) patients with prior (chemo) radiation were evaluated on H&E stains for the following parameters: viable tumor cells, necrosis, swirled keratin debris, foamy histiocytes, bleeding residues, fibrosis, elastosis, pyknotic cells, calcification, cholesterol crystals, multinucleated giant cells, perineural, and vascular invasion. Histological features were correlated with survival outcomes. Results Only the presence / amount (area) of viable tumor cells correlated with a worse clinical outcome (local and regional recurrence-free survival, (LRRFS), distant metastasis-free survival, disease-specific survival, and overall survival, p Conclusion We could confirm the presence of viable tumor cells as a relevant negative prognostic factor after (chemo) radiation. The amount (area) of viable tumor cells further substratified patients with worse LRRFS. None of the other parameters correlated with a distinctive worse outcome. Importantly, the presence of (swirled) keratin debris alone should not be considered viable tumor cells (ypN0).
- Published
- 2023
11. Potential role of hybrid positron emission tomography in pre-operative assessment of primary salivary gland carcinomas
- Author
-
Karimian, Sevda, Hüllner, Martin W, Rupp, Niels J, Freiberger, Sandra N, Broglie, Martina A, Morand, Grégoire B, University of Zurich, and Morand, Grégoire B
- Subjects
2733 Otorhinolaryngology ,Otorhinolaryngology ,10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health ,10045 Clinic for Otorhinolaryngology ,10181 Clinic for Nuclear Medicine ,General Medicine - Published
- 2023
12. Genetic and epigenetic analysis of hepatocellular adenomas with atypical morphological features
- Author
-
Simon Haefliger, Juergen Hench, Colm J O'Rourke, Nathalie Meyer‐Schaller, Sarp Uzun, Joan Saldarriaga, Achim Weber, Luca Mazzucchelli, Philip Jermann, Stephan Frank, Jesper B Andersen, Luigi Terracciano, Christine Sempoux, Matthias S Matter, and University of Zurich
- Subjects
next generation sequencing ,Histology ,CARCINOMA ,NEOPLASM ,hepatocellular adenoma ,610 Medicine & health ,hepatocellular carcinoma ,General Medicine ,liver ,CLASSIFICATION ,Pathology and Forensic Medicine ,10049 Institute of Pathology and Molecular Pathology ,methylation analysis ,epigenetic ,MALIGNANT POTENTIAL PROPOSAL - Abstract
BackgroundHepatocellular adenoma (HCA) is a rare liver tumour, which can have atypical morphological features such as cytological atypia, pseudoglandular architecture, and altered reticulin framework. Little is known about the genetic and epigenetic alterations of such HCAs and whether they show the alterations classically found in hepatocellular carcinoma (HCC) or in HCA without atypical morphology. MethodsWe analysed five HCAs with atypical morphological features and one HCA with transition to HCC. Every tumour was subtyped by immunohistochemistry, sequenced by a targeted NGS panel, and analysed on a DNA methylation microarray. ResultsSubtyping of the five HCAs with atypical features revealed two beta-catenin mutated HCA (b-HCA), two beta-catenin mutated inflammatory HCA (b-IHCA), and one sonic hedgehog activated HCA (shHCA). None of them showed mutations typically found in HCC, such as, e.g. TERT or TP53 mutations. The epigenomic pattern of HCAs with atypical morphological features clustered with reference data for HCAs without atypical morphological features but not with HCC. Similarly, phyloepigenetic trees using the DNA methylation data reproducibly showed that HCAs with morphological atypia are much more similar to nonmalignant samples than to malignant samples. Finally, atypical HCAs showed no relevant copy number variations (CNV). ConclusionIn our series, mutational, DNA methylation, as well as CNV analyses, supported a relationship of atypical HCAs with nonatypical HCAs rather than with HCC. Therefore, in cases with difficult differential diagnosis between HCC and HCA, it might be advisable to perform targeted sequencing and/or combined methylation/copy number profiling.
- Published
- 2023
13. Transplantation of a human liver following 3 days of ex situ normothermic preservation
- Author
-
Clavien, Pierre-Alain, Dutkowski, Philipp, Mueller, Matteo, Eshmuminov, Dilmurodjon, Bautista Borrego, Lucia, Weber, Achim, Muellhaupt, Beat, Sousa Da Silva, Richard X, Burg, Brian R, Rudolf von Rohr, Philipp, Schuler, Martin J, Becker, Dustin, Hefti, Max, Tibbitt, Mark W, University of Zurich, and Clavien, Pierre-Alain
- Subjects
1502 Bioengineering ,Biomedical Engineering ,2204 Biomedical Engineering ,610 Medicine & health ,Bioengineering ,Organ Preservation ,Applied Microbiology and Biotechnology ,Liver Transplantation ,Perfusion ,10219 Clinic for Gastroenterology and Hepatology ,Liver ,10049 Institute of Pathology and Molecular Pathology ,1313 Molecular Medicine ,1305 Biotechnology ,Quality of Life ,2402 Applied Microbiology and Biotechnology ,Humans ,Molecular Medicine ,Biotechnology - Abstract
Current organ preservation methods provide a narrow window (usually12 hours) to assess, transport and implant donor grafts for human transplantation. Here we report the transplantation of a human liver discarded by all centers, which could be preserved for several days using ex situ normothermic machine perfusion. The transplanted liver exhibited normal function, with minimal reperfusion injury and the need for only a minimal immunosuppressive regimen. The patient rapidly recovered a normal quality of life without any signs of liver damage, such as rejection or injury to the bile ducts, according to a 1-year follow up. This inaugural clinical success opens new horizons in clinical research and promises an extended time window of up to 10 days for assessment of viability of donor organs as well as converting an urgent and highly demanding surgery into an elective procedure.
- Published
- 2022
14. Immunohistochemical Expression Pattern of Theragnostic Targets SSTR2 and PSMA in Endolymphatic Sac Tumors: A Single Institution Case Series
- Author
-
Brada, Muriel D, Rushing, Elisabeth J, Bächinger, David, Zoller, Loris, Burger, Irene A, Hüllner, Martin W, Moch, Holger, Huber, Alexander, Eckhard, Andreas H, Rupp, Niels J, and University of Zurich
- Subjects
Oncology ,Otorhinolaryngology ,10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health ,10045 Clinic for Otorhinolaryngology ,10181 Clinic for Nuclear Medicine ,Pathology and Forensic Medicine - Abstract
Background Endolymphatic sac tumors are rare neoplasia characterized by slow growth. However, their clinical impact should not be underestimated, considering their potential for local aggressive behavior and strong association with von Hippel–Lindau syndrome. Therefore, early detection with emerging theragnostic examinations such as 68Ga-DOTATATE-PET/CT might improve patient management and reduce morbidity. Methods We report the clinicopathological features of seven endolymphatic sac tumors. In this cohort, we performed immunohistochemical analysis of somatostatin receptor 2A (SSTR2A) and prostate specific membrane antigen (PSMA) protein expression patterns; two targets providing rationale for novel imaging modalities such as PSMA- or SSTR-targeted PET. Results The tumor cells of all cases were negative for prostate specific membrane antigen and somatostatin receptor 2A, however immunolabeling was consistently detected in intratumoral endothelial cells of endolymphatic sac tumors for PSMA (7/7 cases, 100%), and for SSTR2A (5/7 cases, 71%). Conclusions Our results show a high rate of PSMA and SSTR2A expression in the tumor vasculature of endolymphatic sac tumors. PSMA and SSTR2A can be targeted with appropriate radioligands for diagnostic and therapeutic purposes. This finding provides a rationale for prospective clinical studies to test this approach as a sensitive screening tool for patients with suspected endolymphatic sac tumors including an improved management of von Hippel–Lindau syndrome.
- Published
- 2022
15. Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI
- Author
-
Laudicella, Riccardo, Rüschoff, Jan H, Ferraro, Daniela A, Brada, Muriel D, Hausmann, Daniel, Mebert, Iliana, Maurer, Alexander, Hermanns, Thomas, Eberli, Daniel, Rupp, Niels J, Burger, Irene A, University of Zurich, and Burger, Irene A
- Subjects
Male ,Prostatic Neoplasms ,Gallium Radioisotopes ,610 Medicine & health ,10181 Clinic for Nuclear Medicine ,General Medicine ,Nuclear Medicine and imaging ,10062 Urological Clinic ,Positron Emission Tomography Computed Tomography ,Positron-Emission Tomography ,10049 Institute of Pathology and Molecular Pathology ,Humans ,2741 Radiology, Nuclear Medicine and Imaging ,Radiology, Nuclear Medicine and imaging ,Multiparametric Magnetic Resonance Imaging ,Radiology ,Retrospective Studies - Abstract
Purpose Recently, a significant association was shown between novel growth patterns on histopathology of prostate cancer (PCa) and prostate-specific membrane antigen (PSMA) uptake on [68Ga]PSMA-PET. It is the aim of this study to evaluate the association between these growth patterns and ADC (mm2/1000 s) values in comparison to [68Ga]PSMA uptake on PET/MRI. Methods We retrospectively evaluated patients who underwent [68Ga]PSMA PET/MRI for staging or biopsy guidance, followed by radical prostatectomy at our institution between 07/2016 and 01/2020. The dominant lesion per patient was selected based on histopathology and correlated to PET/MRI in a multidisciplinary meeting, and quantified using SUVmax for PSMA uptake and ADCmean for diffusion restriction. PCa growth pattern was classified as expansive (EXP) or infiltrative (INF) according to its properties of forming a tumoral mass or infiltrating diffusely between benign glands by two independent pathologists. Furthermore, the corresponding WHO2016 ISUP tumor grade was evaluated. The t test was used to compare means, Pearson’s test for categorical correlation, Cohen’s kappa test for interrater agreement, and ROC curve to determine the best cutoff. Results Sixty-two patients were included (mean PSA 11.7 ± 12.5). The interrater agreement between both pathologists was almost perfect with κ = 0.81. While 25 lesions had an EXP-growth with an ADCmean of 0.777 ± 0.109, 37 showed an INF-growth with a significantly higher ADCmean of 1.079 ± 0.262 (p max for the EXP-growth (19.2 ± 10.9) versus the INF-growth (9.4 ± 6.2, p mean could be observed (p = 0.982 and p = 0.861, respectively). Conclusion PCa with INF-growth showed significantly lower SUVmax and higher ADCmean values compared to PCa with EXP-growth. Within the growth groups, ADCmean values were independent from ISUP grading.
- Published
- 2022
16. The vascular gene Apold1 is dispensable for normal development but controls angiogenesis under pathological conditions
- Author
-
Fan, Zheng, Ardicoglu, Raphaela, Batavia, Aashil A, Rust, Ruslan, von Ziegler, Lukas, Waag, Rebecca, Zhang, Jing, Desgeorges, Thibaut, Sturman, Oliver, Dang, Hairuo, Weber, Rebecca, Roszkowski, Martin, Moor, Andreas E, Schwab, Martin E, Germain, Pierre-Luc, Bohacek, Johannes, De Bock, Katrien, University of Zurich, Bohacek, Johannes, and De Bock, Katrien
- Subjects
Cancer Research ,Tumor ,10017 Institute of Anatomy ,Physiology ,EC proliferation ,Clinical Biochemistry ,610 Medicine & health ,11359 Institute for Regenerative Medicine (IREM) ,1314 Physiology ,1308 Clinical Biochemistry ,10124 Institute of Molecular Life Sciences ,Stroke ,Endothelial cell ,10049 Institute of Pathology and Molecular Pathology ,570 Life sciences ,biology ,1306 Cancer Research ,Angiogenesis ,10064 Neuroscience Center Zurich ,Hindlimb ischemia - Abstract
The molecular mechanisms of angiogenesis have been intensely studied, but many genes that control endothelial behavior and fate still need to be described. Here, we characterize the role of Apold1 (Apolipoprotein L domain containing 1) in angiogenesis in vivo and in vitro. Single-cell analyses reveal that - across tissues - the expression of Apold1 is restricted to the vasculature and that Apold1 expression in endothelial cells (ECs) is highly sensitive to environmental factors. Using Apold1(-/-) mice, we find that Apold1 is dispensable for development and does not affect postnatal retinal angiogenesis nor alters the vascular network in adult brain and muscle. However, when exposed to ischemic conditions following photothrombotic stroke as well as femoral artery ligation, Apold1(-/-) mice display dramatic impairments in recovery and revascularization. We also find that human tumor endothelial cells express strikingly higher levels of Apold1 and that Apold1 deletion in mice stunts the growth of subcutaneous B16 melanoma tumors, which have smaller and poorly perfused vessels. Mechanistically, Apold1 is activated in ECs upon growth factor stimulation as well as in hypoxia, and Apold1 intrinsically controls EC proliferation but not migration. Our data demonstrate that Apold1 is a key regulator of angiogenesis in pathological settings, whereas it does not affect developmental angiogenesis, thus making it a promising candidate for clinical investigation., Angiogenesis, 26 (3), ISSN:1573-7209, ISSN:0969-6970
- Published
- 2023
17. WHO 2022 classification of penile and scrotal cancers: updates and evolution
- Author
-
Menon, S, Moch, H, Berney, D M, Cree, I A, Srigley, J R, Tsuzuki, T, Compérat, E, Hartmann, A, Netto, G, Rubin, M A, Gill, A J, Turajlic, S, Tan, P H, Raspollini, M R, Tickoo, S K, Amin, M B, University of Zurich, and Moch, H
- Subjects
2734 Pathology and Forensic Medicine ,10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health ,2722 Histology - Published
- 2023
18. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Author
-
A. Krämer, T. Bochtler, C. Pauli, G. Baciarello, S. Delorme, K. Hemminki, L. Mileshkin, H. Moch, K. Oien, T. Olivier, A. Patrikidou, H. Wasan, G. Zarkavelis, G. Pentheroudakis, K. Fizazi, and University of Zurich
- Subjects
Oncology ,10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health ,Hematology - Published
- 2023
19. B3-Läsionen der Mamma: Histologische, klinische und epidemiologische Aspekte
- Author
-
Varga, Zsuzsanna, Sinn, Peter, Lebeau, Annette, University of Zurich, and Varga, Zsuzsanna
- Subjects
2734 Pathology and Forensic Medicine ,10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health - Published
- 2023
20. Monoclonal antibody-based localization of major diagnostic antigens in metacestode tissue, excretory/secretory products, and extracellular vesicles of Echinococcus species
- Author
-
Kronenberg, Philipp Andreas, Reinehr, Michael, Eichenberger, Ramon M, Hasler, Sina, Laurimäe, Teivi, Weber, Achim, Deibel, Ansgar, Müllhaupt, Beat, Gottstein, Bruno, Müller, Norbert, Hemphill, Andrew, Deplazes, Peter, University of Zurich, Kronenberg, Philipp Andreas, and Deplazes, Peter
- Subjects
10078 Institute of Parasitology ,Microbiology (medical) ,2403 Immunology ,630 Agriculture ,Em2 ,2404 Microbiology ,Immunology ,II/3-10 ,Antigen B ,610 Medicine & health ,2725 Infectious Diseases ,Em18 ,Echinococcus granulosus sensu lato ,Microbiology ,2726 Microbiology (medical) ,EmG3 ,10219 Clinic for Gastroenterology and Hepatology ,Infectious Diseases ,600 Technology ,10049 Institute of Pathology and Molecular Pathology ,579: Mikrobiologie ,570 Life sciences ,biology ,Echinococcus multilocularis ,2B2 - Abstract
Alveolar (AE) and cystic echinococcosis (CE) are severe parasitic zoonoses caused by the larval stages of Echinococcus multilocularis and E. granulosus sensu lato, respectively. A panel of 7 monoclonal antibodies (mAbs) was selected against major diagnostic epitopes of both species. The binding capacity of the mAbs to Echinococcus spp. excretory/secretory products (ESP) was analyzed by sandwich-ELISA, where mAb Em2G11 and mAb EmG3 detected in vitro extravesicular ESP of both E. multilocularis and E. granulosus s.s. These findings were subsequently confirmed by the detection of circulating ESP in a subset of serum samples from infected hosts including humans. Extracellular vesicles (EVs) were purified, and the binding to mAbs was analyzed by sandwich-ELISA. Transmission electron microscopy (TEM) was used to confirm the binding of mAb EmG3 to EVs from intravesicular fluid of Echinococcus spp. vesicles. The specificity of the mAbs in ELISA corresponded to the immunohistochemical staining (IHC-S) patterns performed on human AE and CE liver sections. Antigenic small particles designated as ‘‘spems’’ for E. multilocularis and ‘‘spegs’’ for E. granulosus s.l. were stained by the mAb EmG3IgM, mAb EmG3IgG1, mAb AgB, and mAb 2B2, while mAb Em2G11 reacted with spems and mAb Eg2 with spegs only. The laminated layer (LL) of both species was strongly visualized by using mAb EmG3IgM, mAb EmG3IgG1, mAb AgB, and mAb 2B2. The LL was specifically stained by mAb Em2G11 in E. multilocularis and by mAb Eg2 in E. granulosus s.l. In the germinal layer (GL), including the protoscoleces, a wide staining pattern with all structures of both species was observed with mAb EmG3IgG1, mAb EmG3IgM, mAb AgB, mAb 2B2, and mAb Em18. In the GL and protoscoleces, the mAb Eg2 displayed a strong E. granulosus s.l. specific binding, while mAb Em2G11 exhibited a weak granular E. multilocularis specific reaction. The most notable staining pattern in IHC-S was found with mAb Em18, which solely bound to the GL and protoscoleces of Echinococcus species and potentially to primary cells. To conclude, mAbs represent valuable tools for the visualization of major antigens in the most important Echinococcus species, as well as providing insights into parasite-host interactions and pathogenesis.
- Published
- 2023
21. Nicotinamide N-methyltransferase sustains a core epigenetic program that promotes metastatic colonization in breast cancer
- Author
-
Couto, Joana Pinto, Vulin, Milica, Jehanno, Charly, Coissieux, Marie-May, Hamelin, Baptiste, Schmidt, Alexander, Ivanek, Robert, Sethi, Atul, Bräutigam, Konstantin, Frei, Anja L, Hager, Carolina, Manivannan, Madhuri, Gómez-Miragaya, Jorge, Obradović, Milan Ms, Varga, Zsuzsanna, Koelzer, Viktor H, Mertz, Kirsten D, Bentires-Alj, Mohamed, and University of Zurich
- Subjects
10049 Institute of Pathology and Molecular Pathology ,570 Life sciences ,biology ,610 Medicine & health - Abstract
Metastatic colonization of distant organs accounts for over 90% of deaths related to solid cancers, yet the molecular determinants of metastasis remain poorly understood. Here, we unveil a mechanism of colonization in the aggressive basal-like subtype of breast cancer that is driven by the NAD+ metabolic enzyme nicotinamide N-methyltransferase (NNMT). We demonstrate that NNMT imprints a basal genetic program into cancer cells, enhancing their plasticity. In line, NNMT expression is associated with poor clinical outcomes in patients with breast cancer. Accordingly, ablation of NNMT dramatically suppresses metastasis formation in pre-clinical mouse models. Mechanistically, NNMT depletion results in a methyl overflow that increases histone H3K9 trimethylation (H3K9me3) and DNA methylation at the promoters of PR/SET Domain-5 (PRDM5) and extracellular matrix-related genes. PRDM5 emerged in this study as a pro-metastatic gene acting via induction of cancer-cell intrinsic transcription of collagens. Depletion of PRDM5 in tumor cells decreases COL1A1 deposition and impairs metastatic colonization of the lungs. These findings reveal a critical activity of the NNMT-PRDM5-COL1A1 axis for cancer cell plasticity and metastasis in basal-like breast cancer.
- Published
- 2023
- Full Text
- View/download PDF
22. Analysis of the PARP1, ADP-Ribosylation, and TRIP12 Triad With Markers of Patient Outcome in Human Breast Cancer
- Author
-
Krishnan, Aswini, Spegg, Vincent, Dettwiler, Susanne, Schraml, Peter, Moch, Holger, Dedes, Konstantin, Varga, Zsuzsanna, Altmeyer, Matthias, and University of Zurich
- Subjects
10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health ,Pathology and Forensic Medicine - Published
- 2023
- Full Text
- View/download PDF
23. Immunohistochemistry for hepatitis E virus capsid protein cross-reacts with cytomegalovirus-infected cells: a potential diagnostic pitfall
- Author
-
Lenggenhager, Daniela, Grossmann, Jonas, Gouttenoire, Jérôme, Sempoux, Christine, Weber, Achim, University of Zurich, and Weber, Achim
- Subjects
Histology ,Hepatitis E virus (HEV) ,HEV ORF2 antibody ,Cross-reactivity ,610 Medicine & health ,General Medicine ,2722 Histology ,Immunohistochemistry ,Pathology and Forensic Medicine ,2734 Pathology and Forensic Medicine ,Cytomegalovirus (CMV) antibody ,Pregnancy ,Animals ,Mice ,Humans ,Female ,Hepatitis E virus ,Cytomegalovirus ,Capsid Proteins ,Hepatitis E ,Placenta ,cross-reactivity ,cytomegalovirus (CMV) antibody ,hepatitis E virus (HEV) ,immunohistochemistry ,10049 Institute of Pathology and Molecular Pathology - Abstract
Immunohistochemistry for hepatitis E virus (HEV) ORF2 (capsid) protein is a powerful tool for tissue-based diagnosis of hepatitis E, particularly useful in evaluating abnormal liver values in immunocompromised patients. We report here a previously unobserved reactivity of the HEV ORF2 antibody to human cytomegalovirus (CMV) proteins and contrast the staining patterns encountered in HEV and CMV infection, respectively. As part of a routine diagnostic work-up, the liver biopsy of an immunocompromised patient with elevated liver values was examined histologically for infection with viruses including CMV and HEV. Cytopathic changes were found, suggestive of CMV infection, which was confirmed by immunohistochemistry. Surprisingly, reactivity of a portion of CMV-infected cells with a mouse monoclonal antibody (clone 1E6) against HEV ORF2 protein was also detected. This observation prompted a screening of 22 further specimens (including liver, gastrointestinal, lung, brain and placental biopsies) with confirmed CMV infection/reactivation. Immunoreactivity of CMV-infected cells with HEV ORF2 antibody was observed in 18 of 23 specimens. While the HEV ORF2 antibody showed cytoplasmic, nuclear and canalicular positivity in hepatitis E cases, positivity in CMV-infected cells was limited to the nucleus. In conclusion, the HEV ORF2 antibody (clone 1E6) shows unexpected immunoreactivity against CMV proteins. In contrast to the hepatitis E staining pattern with cytoplasmic, nuclear and occasional canalicular positivity, reactivity in CMV-infected cells is restricted to the nucleus. Awareness of this cross-reactivity and knowledge of the differences in staining patterns will prevent pathologists from misinterpreting positive HEV ORF2 immunohistochemistry in liver specimens., Histopathology, 82 (2), ISSN:0309-0167, ISSN:1365-2559
- Published
- 2023
24. Allgemeine Pathologie
- Author
-
Koelzer, Viktor H, Moch, Holger, Vogt, Peter K, Cerny, Thomas, Karlin, Kirill, University of Zurich, Cerny, Thomas, and Karlin, Kirill
- Subjects
10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health - Published
- 2023
25. The landscape of viral associations in human cancers
- Author
-
Zapatka, Marc, Borozan, Ivan, Brewer, Daniel S, Iskar, Murat, Grundhoff, Adam, Alawi, Malik, Desai, Nikita, Sültmann, Holger, Moch, Holger, PCAWG Pathogens, Cooper, Colin S, Eils, Roland, Ferretti, Vincent, Lichter, Peter, PCAWG Consortium, University of Zurich, and Lichter, Peter
- Subjects
Human Biology & Physiology ,Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17] ,1311 Genetics ,Ecology,Evolution & Ethology ,10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health ,Tumour Biology ,Genetics & Genomics ,Women's cancers Radboud Institute for Health Sciences [Radboudumc 17] ,Structural Biology & Biophysics ,Computational & Systems Biology - Abstract
Here, as part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, for which whole-genome and-for a subset-whole-transcriptome sequencing data from 2,658 cancers across 38 tumor types was aggregated, we systematically investigated potential viral pathogens using a consensus approach that integrated three independent pipelines. Viruses were detected in 382 genome and 68 transcriptome datasets. We found a high prevalence of known tumor-associated viruses such as Epstein-Barr virus (EBV), hepatitis B virus (HBV) and human papilloma virus (HPV; for example, HPV16 or HPV18). The study revealed significant exclusivity of HPV and driver mutations in head-and-neck cancer and the association of HPV with APOBEC mutational signatures, which suggests that impaired antiviral defense is a driving force in cervical, bladder and head-and-neck carcinoma. For HBV, HPV16, HPV18 and adeno-associated virus-2 (AAV2), viral integration was associated with local variations in genomic copy numbers. Integrations at the TERT promoter were associated with high telomerase expression evidently activating this tumor-driving process. High levels of endogenous retrovirus (ERV1) expression were linked to a worse survival outcome in patients with kidney cancer.
- Published
- 2023
26. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification
- Author
-
George J. Netto, Mahul B. Amin, Eva M. Compérat, Anthony J. Gill, Arndt Hartmann, Holger Moch, Santosh Menon, Maria R. Raspollini, Mark A. Rubin, John R. Srigley, Puay Hoon Tan, Satish K. Tickoo, Toyonori Tsuzuki, Samra Turajlic, Ian Cree, Daniel M. Berney, University of Zurich, and Netto, George J
- Subjects
2748 Urology ,Urology ,10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health - Abstract
We present the rationale for keeping the "cancer" label for grade group 1 (GG1) prostate cancer. Maintaining GG1 as the lowest grade outweighs the potential benefits that a benign designation may bring. Patient and surgeon education on the vital role of active surveillance for GG1 cancers and avoidance of overtreatment should be the focus rather than such a drastic change in nomenclature.
- Published
- 2023
- Full Text
- View/download PDF
27. Multiplex imaging of breast cancer lymph node metastases identifies prognostic single-cell populations independent of clinical classifiers
- Author
-
Fischer, Jana Raja, Jackson, Hartland Warren, de Souza, Natalie, Varga, Zsuzsanna, Schraml, Peter, Moch, Holger, Bodenmiller, Bernd, University of Zurich, Jackson, Hartland Warren, and Bodenmiller, Bernd
- Subjects
1300 General Biochemistry, Genetics and Molecular Biology ,10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health ,General Biochemistry, Genetics and Molecular Biology - Abstract
Although breast cancer mortality is largely caused by metastasis, clinical decisions are based on analysis of the primary tumor and on lymph node involvement but not on the phenotype of disseminated cells. Here, we use multiplex imaging mass cytometry to compare single-cell phenotypes of primary breast tumors and matched lymph node metastases in 205 patients. We observe extensive phenotypic variability between primary and metastatic sites and that disseminated cell phenotypes frequently deviate from the clinical disease subtype. We identify single-cell phenotypes and spatial organizations of disseminated tumor cells that are associated with patient survival and a weaker survival association for high-risk phenotypes in the primary tumor. We show that p53 and GATA3 in lymph node metastases provide prognostic information beyond clinical classifiers and can be measured with standard methods. Molecular characterization of disseminated tumor cells is an untapped source of clinically applicable prognostic information for breast cancer., Cell Reports Medicine, 4 (3), ISSN:2666-3791
- Published
- 2023
- Full Text
- View/download PDF
28. Establishment, characterization and functional testing of two novel ex vivo extraskeletal myxoid chondrosarcoma (EMC) cell models
- Author
-
Jana Lucia Bangerter, Kim Jannis Harnisch, Yanjiang Chen, Catherine Hagedorn, Lara Planas-Paz, Chantal Pauli, University of Zurich, and Pauli, Chantal
- Subjects
1307 Cell Biology ,Cancer Research ,10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health ,1306 Cancer Research ,Cell Biology - Abstract
Extraskeletal myxoid chondrosarcoma (EMC) is a malignant mesenchymal neoplasm of uncertain differentiation as classified by the WHO Classification of Tumours 2020. Although often associated with pronlonged survival, EMC has high rates of distant recurrences and disease-associated death. EMCs are translocation sarcomas and harbor in > 90% of the cases an NR4A3 rearrangement. The molecular consequences of the NR4A3 gene fusions are not yet fully elucidated as well-characterized ex vivo cell models for EMC are lacking. Patient-derived ex vivo models are important and essential tools for investigating disease mechanisms associated with diseases that are rare, that exhibit poor prognosis and for the identification of potential novel treatment options. We established two novel EMC ex vivo models (USZ20-EMC1 and USZ22-EMC2) for functional testing and research purposes. USZ20-EMC1 and USZ22-EMC2 were established and maintained as sarco-sphere cell models for several months in culture. The cells were molecularly characterized using DNA sequencing and methylation profiling. Both cell models represent their native tumor tissue as confirmed by histomorphology and their molecular profiles, suggesting that native tumor cell function can be recapitulated in the ex vivo models. Using a functional screening approach, novel anti-cancer drug sensitivities including potential synergistic combinations were identified. In conclusion, two novel EMC ex vivo cell models (USZ20-EMC1 and USZ22-EMC2) were successfully established and characterized from native tumor tissues. Both cell models will be useful tools for further investigating disease mechanisms and for answering basic and translational research questions.
- Published
- 2023
29. Towards virtual histology with X-ray grating interferometry
- Author
-
Polikarpov, M, Vila-Comamala, J, Wang, Z, Pereira, A, van Gogh, S, Gasser, C, Jefimovs, K, Romano, L, Varga, Z, Lång, K, Schmeltz, M, Tessarini, S, Rawlik, M, Jermann, E, Lewis, S, Yun, W, Stampanoni, M, and University of Zurich
- Subjects
synchrotron-radiation ,10049 Institute of Pathology and Molecular Pathology ,mammography ,resolution ,610 Medicine & health ,phase-contrast ,visualization - Abstract
Breast cancer is the most common type of cancer worldwide. Diagnosing breast cancer relies on clinical examination, imaging and biopsy. A core-needle biopsy enables a morphological and biochemical characterization of the cancer and is considered the gold standard for breast cancer diagnosis. A histopathological examination uses high-resolution microscopes with outstanding contrast in the 2D plane, but the spatial resolution in the third, Z-direction, is reduced. In the present paper, we propose two high-resolution table-top systems for phase-contrast X-ray tomography of soft-tissue samples. The first system implements a classical Talbot–Lau interferometer and allows to perform ex-vivo imaging of human breast samples with a voxel size of 5.57 μm. The second system with a comparable voxel size relies on a Sigray MAAST X-ray source with structured anode. For the first time, we demonstrate the applicability of the latter to perform X-ray imaging of human breast specimens with ductal carcinoma in-situ. We assessed image quality of both setups and compared it to histology. We showed that both setups made it possible to target internal features of breast specimens with better resolution and contrast than previously achieved, demonstrating that grating-based phase-contrast X-ray CT could be a complementary tool for clinical histopathology., Scientific Reports, 13 (1), ISSN:2045-2322
- Published
- 2023
- Full Text
- View/download PDF
30. The impact of intraoperative frozen section in patients with clinically node-negative breast cancer (cN0/ycN0) who received neoadjuvant systemic therapy
- Author
-
Güth, Uwe, Elfgen, Constanze, Zadeh, Shadi Najaf, Meier, Simon, Varga, Zsuzsanna, Tinguely, Marianne, Papassotiropoulos, Bärbel, Däster, Kavitha, Tausch, Christoph J, University of Zurich, and Güth, Uwe
- Subjects
Oncology ,10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health ,2730 Oncology ,Surgery ,General Medicine ,2746 Surgery - Published
- 2023
- Full Text
- View/download PDF
31. Sexual dimorphism in COVID-19: potential clinical and public health implications
- Author
-
Bechmann, Nicole, Barthel, Andreas, Schedl, Andreas, Herzig, Stephan, Varga, Zsuzsanna, Gebhard, Catherine, Mayr, Manuel, Hantel, Constanze, Beuschlein, Felix, Wolfrum, Christian, Perakakis, Nikolaos, Poston, Lucilla, Andoniadou, Cynthia L, Siow, Richard, Gainetdinov, Raul R, Dotan, Arad, Shoenfeld, Yehuda, Mingrone, Geltrude, Bornstein, Stefan R, and University of Zurich
- Subjects
Male ,Personal View ,Hypothalamo-Hypophyseal System ,Sex Characteristics ,Endocrinology, Diabetes and Metabolism ,10265 Clinic for Endocrinology and Diabetology ,Pituitary-Adrenal System ,COVID-19 ,610 Medicine & health ,Settore MED/13 - ENDOCRINOLOGIA ,10181 Clinic for Nuclear Medicine ,Health Status Disparities ,Settore MED/17 - MALATTIE INFETTIVE ,Diabetes and Metabolism ,Post-Acute COVID-19 Syndrome ,Endocrinology ,10049 Institute of Pathology and Molecular Pathology ,Internal Medicine ,Humans ,Female ,Public Health - Abstract
Current evidence suggests that severity and mortality of COVID-19 is higher in men than in women, whereas women might be at increased risk of COVID-19 reinfection and development of long COVID. Differences between sexes have been observed in other infectious diseases and in the response to vaccines. Sex-specific expression patterns of proteins mediating virus binding and entry, and divergent reactions of the immune and endocrine system, in particular the hypothalamic-pituitary-adrenal axis, in response to acute stress might explain the higher severity of COVID-19 in men. In this Personal View, we discuss how sex hormones, comorbidities, and the sex chromosome complement influence these mechanisms in the context of COVID-19. Due to its role in the severity and progression of SARS-CoV-2 infections, we argue that sexual dimorphism has potential implications for disease treatment, public health measures, and follow-up of patients predisposed to the development of long COVID. We suggest that sex differences could be considered in future pandemic surveillance and treatment of patients with COVID-19 to help to achieve better disease stratification and improved outcomes.
- Published
- 2022
32. Reappraisal of Grading in Intestinal-Type Sinonasal Adenocarcinoma: Tumor Budding as an Independent Prognostic Parameter
- Author
-
Meerwein, Christian M, Brada, Muriel D, Soyka, Michael B, Holzmann, David, Rupp, Niels J, University of Zurich, and Meerwein, Christian M
- Subjects
2734 Pathology and Forensic Medicine ,2733 Otorhinolaryngology ,Oncology ,Otorhinolaryngology ,10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health ,10045 Clinic for Otorhinolaryngology ,2730 Oncology ,Pathology and Forensic Medicine - Abstract
Since sinonasal intestinal-type adenocarcinomas (ITAC) show resemblance to colorectal adenocarcinomas, we aimed to investigate novel prognostic factors of outcome, with particular focus on the role of tumor budding (TB). Retrospective clinico-pathological single-institution study on consecutive ITAC patients between 1996 and 2020. Histopathological parameters including conventional subtypes and TB features (low, intermediate, high) were evaluated with the aid of pancytokeratin (AE1/AE3) immunohistochemical staining. Parameters were correlated to clinical data and outcome. A total of 31 ITAC patients were included. Overall, 19/31 patients (61.3%) presented with stage III/IV disease. Presence of lymph node or distant metastases was rare (1/31 patient, 3.2%). Treatment protocols consisted of tumor resection in 30/31 patients (96.8%) and primary radiochemotherapy in 1/31 patient (3.2%). Adjuvant radiation therapy was conducted in 20/30 surgically treated patients (66.7%). The 3- and 5-year overall survival (OS) was 83.9% and 78.3% and the 3- and 5-years disease-specific survival (DSS) 83.7% % and 78.5%, respectively. The presence of intermediate/high TB (defined as ≥ 5 buds) was associated with both, worse DSS (log rank p = 0.03) and OS (log rank p = 0.006). No patient with low TB revealed progressive disease or died of the disease. No association between TB and tumor stage or conventional tumor subtype was found. Tumor budding seems to be an independent prognostic factor of worse outcome in ITAC.
- Published
- 2022
33. Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients
- Author
-
Freiberger, Sandra N, Holzmann, David, Morand, Grégoire B, Hüllner, Martin, Levesque, Mitchell Paul, Dummer, Reinhard, Koelzer, Viktor H, Rupp, Niels J, University of Zurich, and Freiberger, Sandra N
- Subjects
Cancer Research ,Oncology ,10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health ,10045 Clinic for Otorhinolaryngology ,2730 Oncology ,1306 Cancer Research ,General Medicine ,10181 Clinic for Nuclear Medicine - Abstract
Purpose Immunotherapy using immune checkpoint inhibitors (ICI) has revolutionized cancer treatment in recent years, particularly in melanoma. While response to immunotherapy is associated with high tumor mutational burden (TMB), PD-L1 expression, and microsatellite instability in several cancers, tumors lacking these biomarkers can still respond to this treatment. Especially, mucosal melanoma, commonly exhibiting low TMB compared to cutaneous melanoma, may respond to immunotherapy with immune checkpoint inhibitors. Therefore, the aim of our study was to investigate novel biomarkers in mucosal melanoma that predict response to combined ipilimumab and nivolumab. Methods We investigated 10 tumor samples from 10 patients (three responders, seven non-responders) before treatment and six tumor samples from five patients after progression using a targeted Next Generation Sequencing (NGS) gene expression panel. The findings were corroborated with an independent method (i.e., immunohistochemical staining) on the same 10 tumor samples before treatment and, to increase the cohort, in addition on three tumor samples before treatment of more recent patients (one responder, two non-responders). Results With the targeted gene expression panel, we found the three tumor testis antigens CTAG1B (NY-ESO-1), MAGE-A3, and MAGE-A4 to be predominantly expressed in responding tumors. This marker panel was either not or not completely expressed in non-responders (p Conclusion In conclusion, these three biomarkers await validation in a larger patient cohort and could be easily used in future routine diagnostics to predict the outcome of ipilimumab/nivolumab combination therapy in mucosal melanoma patients.
- Published
- 2022
34. Vaccination with designed neopeptides induces intratumoral, cross-reactive CD4+ T cell responses in glioblastoma
- Author
-
Jian Wang, Tobias Weiss, Marian C. Neidert, Nora C. Toussaint, Reza Naghavian, Carla Sellés Moreno, Magdalena Foege, Paula Tomas Ojer, Gioele Medici, Ivan Jelcic, Daniel Schulz, Elisabeth Rushing, Susanne Dettwiler, Barbara Schrörs, Joo Heon Shin, Ron McKay, Catherine J. Wu, Andreas Lutterotti, Mireia Sospedra, Holger Moch, Erich F. Greiner, Bernd Bodenmiller, Luca Regli, Michael Weller, Patrick Roth, Roland Martin, and University of Zurich
- Subjects
Cancer Research ,Oncology ,10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health ,11493 Department of Quantitative Biomedicine ,10040 Clinic for Neurology - Abstract
Purpose: The low mutational load of some cancers is considered one reason for the difficulty to develop effective tumor vaccines. To overcome this problem, we developed a strategy to design neopeptides through single amino acid mutations to enhance their immunogenicity. Experimental Design: Exome and RNA sequencing as well as in silico HLA-binding predictions to autologous HLA molecules were used to identify candidate neopeptides. Subsequently, in silico HLA-anchor placements were used to deduce putative T-cell receptor (TCR) contacts of peptides. Single amino acids of TCR contacting residues were then mutated by amino acid replacements. Overall, 175 peptides were synthesized and sets of 25 each containing both peptides designed to bind to HLA class I and II molecules applied in the vaccination. Upon development of a tumor recurrence, the tumor-infiltrating lymphocytes (TIL) were characterized in detail both at the bulk and clonal level. Results: The immune response of peripheral blood T cells to vaccine peptides, including natural peptides and designed neopeptides, gradually increased with repetitive vaccination, but remained low. In contrast, at the time of tumor recurrence, CD8+ TILs and CD4+ TILs responded to 45% and 100%, respectively, of the vaccine peptides. Furthermore, TIL-derived CD4+ T-cell clones showed strong responses and tumor cell lysis not only against the designed neopeptide but also against the unmutated natural peptides of the tumor. Conclusions: Turning tumor self-peptides into foreign antigens by introduction of designed mutations is a promising strategy to induce strong intratumoral CD4+ T-cell responses in a cold tumor like glioblastoma., Clinical Cancer Research, 28 (24), ISSN:1078-0432, ISSN:1557-3265
- Published
- 2022
35. ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer
- Author
-
Dilara Akhoundova, Saskia Hussung, Smruthy Sivakumar, Antonia Töpfer, Markus Rechsteiner, Abdullah Kahraman, Fabian Arnold, Florian Angst, Christian Britschgi, Martin Zoche, Holger Moch, Achim Weber, Ethan Sokol, Ralph M. Fritsch, University of Zurich, and Fritsch, Ralph M
- Subjects
Proto-Oncogene Proteins B-raf ,Gene Rearrangement ,Cancer Research ,Lung Neoplasms ,610 Medicine & health ,Genomics ,Protein-Tyrosine Kinases ,Protein Serine-Threonine Kinases ,Proto-Oncogene Proteins p21(ras) ,Crizotinib ,Oncology ,Proto-Oncogene Proteins ,10049 Institute of Pathology and Molecular Pathology ,10032 Clinic for Oncology and Hematology ,Humans ,2730 Oncology ,1306 Cancer Research ,Reactive Oxygen Species ,Colorectal Neoplasms ,Microsatellite Repeats - Abstract
c-Ros oncogene 1, receptor tyrosine kinase (ROS1) genomic rearrangements have been reported previously in rare cases of colorectal cancer (CRC), yet little is known about the frequency, molecular characteristics, and therapeutic vulnerabilities of ROS1-driven CRC. We analyzed a clinical dataset of 40 589 patients with CRC for ROS1 genomic rearrangements and their associated genomic characteristics (Foundation Medicine, Inc [FMI]). We moreover report the disease course and treatment response of an index patient with ROS1-rearranged metastatic CRC. ROS1 genomic rearrangements were identified in 34 (0.08%) CRC samples. GOPC-ROS1 was the most common ROS1 fusion identified (11 samples), followed by TTC28-ROS1 (3 samples). Four novel 5' gene partners of ROS1 were identified (MCM9, SRPK1, EPHA6, P4HA1). Contrary to previous reports on fusion-positive CRC, ROS1-rearrangements were found exclusively in microsatellite stable (MSS) CRCs. KRAS mutations were significantly less abundant in ROS1-rearranged vs ROS1 wild type cases. The index patient presented with chemotherapy-refractory metastatic right-sided colon cancer harboring GOPC-ROS1. Molecularly targeted treatment with crizotinib induced a rapid and sustained partial response. After 15 months on crizotinib disseminated tumor progression occurred and KRAS Q61H emerged in tissue and liquid biopsies. ROS1 rearrangements define a small, yet therapeutically actionable molecular subgroup of MSS CRC. In summary, the high prevalence of GOPC-ROS1 and noncanonical ROS1 fusions pose diagnostic challenges. We advocate NGS-based comprehensive molecular profiling of MSS CRCs that are wild type for RAS and BRAF and patient enrollment in precision trials.
- Published
- 2022
36. Comparison of calling pipelines for whole genome sequencing: an empirical study demonstrating the importance of mapping and alignment
- Author
-
Raphael O. Betschart, Alexandre Thiéry, Domingo Aguilera-Garcia, Martin Zoche, Holger Moch, Raphael Twerenbold, Tanja Zeller, Stefan Blankenberg, Andreas Ziegler, University of Zurich, and Ziegler, Andreas
- Subjects
1000 Multidisciplinary ,Multidisciplinary ,10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health - Abstract
Rapid advances in high-throughput DNA sequencing technologies have enabled the conduct of whole genome sequencing (WGS) studies, and several bioinformatics pipelines have become available. The aim of this study was the comparison of 6 WGS data pre-processing pipelines, involving two mapping and alignment approaches (GATK utilizing BWA-MEM2 2.2.1, and DRAGEN 3.8.4) and three variant calling pipelines (GATK 4.2.4.1, DRAGEN 3.8.4 and DeepVariant 1.1.0). We sequenced one genome in a bottle (GIAB) sample 70 times in different runs, and one GIAB trio in triplicate. The truth set of the GIABs was used for comparison, and performance was assessed by computation time, F1 score, precision, and recall. In the mapping and alignment step, the DRAGEN pipeline was faster than the GATK with BWA-MEM2 pipeline. DRAGEN showed systematically higher F1 score, precision, and recall values than GATK for single nucleotide variations (SNVs) and Indels in simple-to-map, complex-to-map, coding and non-coding regions. In the variant calling step, DRAGEN was fastest. In terms of accuracy, DRAGEN and DeepVariant performed similarly and both superior to GATK, with slight advantages for DRAGEN for Indels and for DeepVariant for SNVs. The DRAGEN pipeline showed the lowest Mendelian inheritance error fraction for the GIAB trios. Mapping and alignment played a key role in variant calling of WGS, with the DRAGEN outperforming GATK.
- Published
- 2022
37. Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project
- Author
-
Jan Hendrik Rüschoff, Martina Haberecker, Zoi Tsourti, Kristiaan Nackaerts, Marc de Perrot, Luka Brcic, Ernest Nadal, Sotirios Tsimpoukis, Steven G. Gray, Luca Ampollini, Joachim G. Aerts, Emanuela Felley-Bosco, Michaela B. Kirschner, Kim Monkhorst, Birgit Weynand, Fatemeh Bavaghar-Zaeimi, Miroslav Samarzija, Roger Llatjos, Stephen P. Finn, Enrico Silini, Jan von der Thüsen, Nesa Marti, Karerina Vervita, Roswitha Kammler, Solange Peters, Rolf A. Stahel, Paul Baas, Isabelle Opitz, Rolf Stahel, Anita Hiltbrunner, Rosita Kammler, Patrick Vagenknecht, Barbara Ruepp, Urania Dafni, Panagiota Zygoura, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Androniki Stavrou, Jan H. Rüschoff, Susanne Dettwiler, Fabiola Prutek, Christiane Mittmann, Bart Vrugt, Martina Friess, Alessandra Matter, Chloé Spichiger-Häusermann, Eric Verbeken, Birgit Weyenand, Liesbet Peeters, Marcello Tiseo, Enrico Maria Silini, Luigi Ventura, Letizia Gnetti, Paolo Carbognani, Fatemeh B. Zaeimi, Sven Seiwerth, Marko Jakopovic, Felipe Cardenal, Susana Lorente, Konstantinos Syrigos, Ioannis Vamvakaris, Paraskevi Boura, Steven Gray, Mutaz Mohammed Nur, Anne-Marie Baird, Martin Barr, Sinead Cuffe, Kathy Gately, Joachim Aerts, University of Zurich, Pulmonary Medicine, and Pathology
- Subjects
Mesothelioma ,Phosphatidylinositol 3-Kinases / metabolism ,Ribosomal Protein S6 ,Lung Neoplasms ,Pronòstic mèdic ,10255 Clinic for Thoracic Surgery ,Pleural Neoplasms ,Lung Neoplasms / pathology ,Mesothelioma, Malignant ,Pleural Neoplasms / pathology ,610 Medicine & health ,Sarcoma ,Prognosis ,Pathology and Forensic Medicine ,Phosphatidylinositol 3-Kinases ,Mesotelioma ,10049 Institute of Pathology and Molecular Pathology ,Càncer de pulmó ,Pleura ,Humans ,Lung cancer ,ETOP Mesoscape consortium ,Mesothelioma / pathology - Abstract
Pleural mesothelioma (PM) is an aggressive malignancy with poor prognosis. Although histology and pathologic stage are important prognostic factors, better prognostic biomarkers are needed. The ribosomal protein S6 is a downstream target of the phosphatidylinositol 3-kinase (PI3K) pathway involved in protein synthesis and cell proliferation. In previous studies, low phosphorylated S6 (pS6) immunoreactivity was significantly correlated with longer progression-free survival (PFS) and overall survival (OS) in PM patients. We aimed to correlate pS6 expression to clinical data in a large multi-centre PM cohort as part of the European Thoracic Oncology Platform (ETOP) Mesoscape project. Tissue Micro Arrays (TMAs) of PM were constructed and expression of pS6 was evaluated by a semi-quantitatively aggregate H-score. Expression results were correlated to patient characteristics as well as OS/PFS. pS6 IHC results of 364 patients from 9 centres, diagnosed between 1999 and 2017 were available. The primary histology of included tumours was epithelioid (70.3%), followed by biphasic (24.2%) and sarcomatoid (5.5%). TMAs included both treatment-naïve and tumour tissue taken after induction chemotherapy. High pS6 expression (181 patients with H-score>1.41) was significantly associated with less complete resection. In the overall cohort, OS/PFS were not significantly different between pS6-low and pS6-high patients. In a subgroup analysis non-epithelioid (biphasic and sarcomatoid) patients with high pS6 expression showed a significantly shorter OS (p
- Published
- 2022
38. PD-1T TILs as a predictive biomarker for clinical benefit to PD-1 blockade in patients with advanced NSCLC
- Author
-
Karlijn Hummelink, Vincent van der Noort, Mirte Muller, Robert D. Schouten, Ferry Lalezari, Dennis Peters, Willemijn S.M.E. Theelen, Viktor H. Koelzer, Kirsten D. Mertz, Alfred Zippelius, Michel M. van den Heuvel, Annegien Broeks, John B.A.G. Haanen, Ton N. Schumacher, Gerrit A. Meijer, Egbert F. Smit, Kim Monkhorst, Daniela S. Thommen, and University of Zurich
- Subjects
Cancer Research ,Oncology ,10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health ,Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9] - Abstract
Purpose: Durable clinical benefit to PD-1 blockade in non–small cell lung cancer (NSCLC) is currently limited to a small fraction of patients, underlining the need for predictive biomarkers. We recently identified a tumor-reactive tumor-infiltrating T lymphocyte (TIL) pool, termed PD-1T TILs, with predictive potential in NSCLC. Here, we examined PD-1T TILs as biomarker in NSCLC. Experimental Design: PD-1T TILs were digitally quantified in 120 baseline samples from advanced NSCLC patients treated with PD-1 blockade. Primary outcome was disease control (DC) at 6 months. Secondary outcomes were DC at 12 months and survival. Exploratory analyses addressed the impact of lesion-specific responses, tissue sample properties, and combination with other biomarkers on the predictive value of PD-1T TILs. Results: PD-1T TILs as a biomarker reached 77% sensitivity and 67% specificity at 6 months, and 93% and 65% at 12 months, respectively. Particularly, a patient group without clinical benefit was reliably identified, indicated by a high negative predictive value (NPV) (88% at 6 months, 98% at 12 months). High PD-1T TILs related to significantly longer progression-free (HR 0.39, 95% CI, 0.24–0.63, P < 0.0001) and overall survival (HR 0.46, 95% CI, 0.28–0.76, P < 0.01). Predictive performance was increased when lesion-specific responses and samples obtained immediately before treatment were assessed. Notably, the predictive performance of PD-1T TILs was superior to PD-L1 and tertiary lymphoid structures in the same cohort. Conclusions: This study established PD-1T TILs as predictive biomarker for clinical benefit to PD-1 blockade in patients with advanced NSCLC. Most importantly, the high NPV demonstrates an accurate identification of a patient group without benefit. See related commentary by Anagnostou and Luke, p. 4835
- Published
- 2022
39. Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene
- Author
-
Fischer, Alessa, Bankel, Lorenz, Hiltbrunner, Stefanie, Rechsteiner, Markus, Rüschoff, Jan H, Rushing, Elisabeth Jane, Britschgi, Christian, Curioni-Fontecedro, Alessandra, University of Zurich, and Curioni-Fontecedro, Alessandra
- Subjects
Proto-Oncogene Proteins B-raf ,Cancer Research ,Lung Neoplasms ,DNA Copy Number Variations ,610 Medicine & health ,Genomics ,Proto-Oncogene Proteins c-met ,B7-H1 Antigen ,Proto-Oncogene Proteins p21(ras) ,Oncology ,Carcinoma, Non-Small-Cell Lung ,10049 Institute of Pathology and Molecular Pathology ,Mutation ,10032 Clinic for Oncology and Hematology ,Humans ,2736 Pharmacology (medical) ,Pharmacology (medical) ,2730 Oncology ,1306 Cancer Research - Abstract
Mesenchymal-to-epithelial transition (MET) exon 14 skipping mutations and MET gene amplification occur in 3-5% of non-small cell lung cancer (NSCLC) patients. Tyrosine kinase inhibitors (TKIs) targeting MET alterations have shown promising results in these patients.The aim of this study was to describe the genomic profile, PD-L1 expression and clinicopathological features of MET dysregulated NSCLC.We identified 188 patients with advanced-stage NSCLC with data on MET expression by immunohistochemistry (IHC). IHC for PD-L1 expression was performed in 131 patient samples, and next-generation sequencing (NGS) analysis was performed in 109 patient samples.MET exon 14 skipping alterations were identified in 16 (14.7%) samples, MET amplifications with cut-off ≥4 copy number variations were identified in 11 (10.1%) samples, and an oncogenic MET mutation (MET p.D1228N) was identified in 1 (0.9%) sample. 12/15 tumors (80.0%) harboring MET exon 14 alterations and 7/11 (63.6%) MET-amplified tumors expressed PD-L1 in ≥1% of tumor cells. Tumors harboring MET exon 14 skipping alterations expressed PD-L1 more frequently than MET wild-type IHC-positive tumors (p = 0.045). Twenty-five percent of MET exon 14-altered cases and 33% of MET-amplified cases harbored potentially targetable oncogenic co-mutations in KRAS, BRAF, and EGFR. The most frequent co-occurring mutations in all MET-altered tumors were TP53, KRAS, BRAF, and CDK4.We demonstrated that MET exon 14 skipping alterations and MET amplification are not mutually exclusive to other oncogenic co-mutations, and report the association of genomic MET alterations with PD-L1 expression. Since genomic MET alterations are emerging targets requiring upfront treatment, optimal understanding of the co-mutational landscape for this patient population is needed.
- Published
- 2022
40. Author response to: Anatomy of the neural fibers at the superior mesenteric artery-a cadaver study
- Author
-
Reinehr, Michael D, Vuille-Dit-Bille, Raphael N, Staerkle, Ralph F, University of Zurich, and Staerkle, Ralph F
- Subjects
10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health ,2746 Surgery - Published
- 2022
41. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours
- Author
-
Holger Moch, Mahul B. Amin, Daniel M. Berney, Eva M. Compérat, Anthony J. Gill, Arndt Hartmann, Santosh Menon, Maria R. Raspollini, Mark A. Rubin, John R. Srigley, Puay Hoon Tan, Satish K. Tickoo, Toyonori Tsuzuki, Samra Turajlic, Ian Cree, George J. Netto, University of Zurich, and Moch, Holger
- Subjects
Male ,2748 Urology ,Urology ,Papillomavirus Infections ,Genome Integrity & Repair ,Neuroectodermal Tumors ,Receptor Protein-Tyrosine Kinases ,610 Medicine & health ,Genitalia, Male ,Neoplasms, Germ Cell and Embryonal ,Tumour Biology ,World Health Organization ,Kidney Neoplasms ,Signalling & Oncogenes ,Testicular Neoplasms ,10049 Institute of Pathology and Molecular Pathology ,Humans ,Carcinoma, Renal Cell ,Genetics & Genomics ,Computational & Systems Biology - Abstract
The fifth edition of the World Health Organization (WHO) classification of urogenital tumours (WHO "Blue Book"), published in 2022, contains significant revisions. This review summarises the most relevant changes for renal, penile, and testicular tumours. In keeping with other volumes in the fifth edition series, the WHO classification of urogenital tumours follows a hierarchical classification and lists tumours by site, category, family, and type. The section "essential and desirable diagnostic criteria" included in the WHO fifth edition represents morphologic diagnostic criteria, combined with immunohistochemistry and relevant molecular tests. The global introduction of massive parallel sequencing will result in a diagnostic shift from morphology to molecular analyses. Therefore, a molecular-driven renal tumour classification has been introduced, taking recent discoveries in renal tumour genomics into account. Such novel molecularly defined epithelial renal tumours include SMARCB1-deficient medullary renal cell carcinoma (RCC), TFEB-altered RCC, Alk-rearranged RCC, and ELOC-mutated RCC. Eosinophilic solid and cystic RCC is a novel morphologically defined RCC entity. The diverse morphologic patterns of penile squamous cell carcinomas are grouped as human papillomavirus (HPV) associated and HPV independent, and there is an attempt to simplify the morphologic classification. A new chapter with tumours of the scrotum has been introduced. The main nomenclature of testicular tumours is retained, including the use of the term "germ cell neoplasia in situ" (GCNIS) for the preneoplastic lesion of most germ cell tumours and division from those not derived from GCNIS. Nomenclature changes include replacement of the term "primitive neuroectodermal tumour" by "embryonic neuroectodermal tumour" to separate these tumours clearly from Ewing sarcoma. The term "carcinoid" has been changed to "neuroendocrine tumour", with most examples in the testis now classified as "prepubertal type testicular neuroendocrine tumour".
- Published
- 2022
42. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors
- Author
-
Netto, George J, Amin, Mahul B, Berney, Daniel M, et al, Moch, Holger, University of Zurich, and Netto, George J
- Subjects
2748 Urology ,10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health - Published
- 2022
43. PIK3CA Mutational Analysis in Patients With Macrodactyly
- Author
-
Jakob Becker, Ulrike Camenisch Gross, Daniel M Weber, Lisa Weibel, Martin Theiler, Simone Brandt, Peter K Bode, and University of Zurich
- Subjects
Phosphatidylinositol 3-Kinases ,Class I Phosphatidylinositol 3-Kinases ,10049 Institute of Pathology and Molecular Pathology ,Pediatrics, Perinatology and Child Health ,Mutation ,Humans ,Infant ,610 Medicine & health ,General Medicine ,10220 Clinic for Surgery ,Pathology and Forensic Medicine ,Retrospective Studies ,Musculoskeletal Abnormalities - Abstract
Background Somatic mosaicism for PIK3CA mutations causes various types of growth disorders, which have been summarized under the term PROS ( PIK3CA related overgrowth spectrum). Targeted therapy with PI3K inhibitors seems to be a promising alternative for severe PROS cases. Therefore, PIK3CA testing may become more relevant in the future. Methods We report on 14 PROS patients, who had surgery for macrodactyly in the majority of cases. Clinical data were retrieved from the patient’s records. Macroscopic and microscopic findings were retrospectively reviewed. Mutational analysis was performed on formalin-fixed paraffin-embedded (FFPE) material. Results Patient age ranged from 7 months to 35 years. Five patients showed additional anomalies. One patient had CLOVES syndrome. The majority of the specimens were ray resections characterized by hypertrophic fat tissue. Overall, microscopy was subtle. The abnormal adipose tissue showed lobules exhibiting at least focally fibrous septa. In each case, we could detect a PIK3CA mutation. Conclusion Histology of affected fat tissue in PROS patients is overall nonspecific. Therefore, mutational analysis represents the key to the diagnosis, especially in unclear clinical cases. We demonstrated that FFPE material is suitable for PIK3CA testing, which can be considered as basis for targeted therapy with PI3K inhibitors.
- Published
- 2022
44. Prognostic relevance of mixed histological subtypes in invasive breast carcinoma: a retrospective analysis
- Author
-
Rechsteiner, Anna, Dietrich, Daniel, Varga, Zsuzsanna, University of Zurich, and Varga, Zsuzsanna
- Subjects
Cancer Research ,Oncology ,10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health ,2730 Oncology ,1306 Cancer Research ,General Medicine - Abstract
Purpose The prognostic and therapeutic power of special histological subtypes in breast cancer in pure form or in combination with other histological subtypes is still not established, and diagnostic guidelines are cautious regarding prognostic power based on the histological subtype alone. Therapy decisions are guided in most cases independently of the histological subtype and are directed by biomarkers and tumor stage. In this study, we analyzed a comprehensive large retrospective breast cancer cohort with a special focus on histological subtype (other than ductal non-special type or lobular carcinoma) and correlated pure or mixed histological forms with pathological tumor stage and overall disease-free survival. Materials and methods A total of 827 breast cancer cases with pure or mixed special histological types were retrospectively analyzed. Survival information was available in 645 of 827 cases. Results A total of 293 cases had pure forms, and 534 cases had mixed histological subtypes. The most common pure special types were mucinous (23.9%), micropapillary (21.2%), high-grade metaplastic (13%), male breast cancer (8.2%), cribriform (6.8%), metastases (6.1%), apocrine and papillary (each 5.46%), NST with medullary and clear cell pattern (up to 3.4%) and high-grade neuroendocrine carcinomas (2.7%). Mixed forms were most frequently encountered in NST carcinomas with micropapillary components (41.8%), followed by mucinous (9.93%) and cribriform (6.74%) mixed patterns. In univariate analysis, no pure form had prognostic relevance compared with any mixed form with the basic pure element. Pooling pure histological subtypes with tumor stage and age in a linear random-effects model, the cribriform subtype had the most favorable prognosis, while male breast cancer showed the poorest outcome (p p Conclusion Our results show that the analyzed special histological breast cancer subtypes (other than ductal and lobular carcinomas) do not carry prognostic information alone, either in pure form or in any combination with other subtypes. Prognostic groups including special subtypes, however, can strongly stratify breast cancer if tumor stage, age and biomarkers are included in the prognostic measurements.
- Published
- 2022
45. Prognostic relevance of mixed histological subtypes in invasive breast carcinoma: a retrospective analysis
- Author
-
Rechsteiner, Anna, University of Zurich, and Rechsteiner, Anna
- Subjects
UZHDISS UZH Dissertations ,10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health - Published
- 2022
46. Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohort
- Author
-
Bubendorf, Lukas, Zoche, Martin, Dafni, Urania, Rüschoff, Jan Hendrik, Prince, Spasenija Savic, Marti, Nesa, Stavrou, Androniki, Kammler, Roswitha, Finn, Stephen P, Moch, Holger, Peters, Solange, Stahel, Rolf A, University of Zurich, and Stahel, Rolf A
- Subjects
Pulmonary and Respiratory Medicine ,Cancer Research ,Oncology ,2740 Pulmonary and Respiratory Medicine ,10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health ,2730 Oncology ,1306 Cancer Research - Abstract
The primary objective of this study is to evaluate tumor mutational burden (TMB), its associations with selected clinicopathological and molecular characteristics as well as its clinical significance, in a retrospective cohort of surgically resected stage I-II lung adenocarcinomas, subset of the ETOP Lungscape cohort.TMB was evaluated on tumor DNA extracted from resected primary lung adenocarcinomas, based on FoundationOne®CDx (F1CDx) genomic profiling, centrally performed at the University Hospital Zurich. The F1CDx test sequences the complete exons of 324 cancer-related genes and detects substitutions, insertions and deletions (indels), copy number alterations and gene rearrangements. In addition, the genomic biomarkers TMB and microsatellite instability (MSI) are analyzed.In the Lungscape cohort, TMB was assessed in 78 surgically resected lung adenocarcinomas from two Swiss centers (62 % males, 55 %/45 % stage I/II). Median TMB was 7.6 Muts/Mb, with TMB high (≥10 Muts/Mb) in 40 % of cases (95 %CI:29 %-52 %). The most frequently mutated genes were TP53/KRAS/EGFR/MLL2 detected in 58 %/38 %/33 %/30 % of samples, respectively. TMB was significantly higher among males (TMB high: 50 % vs 23 % in females, p = 0.032), as well as among current/former smokers (TMB high: 44 % vs 8 % in never smokers, p = 0.023). Furthermore, TMB was significantly higher in TP53 mutated than in non-mutated patients (TMB high: 60 % vs 12 %, p 0.001), while it was higher in EGFR non-mutated patients compared to EGFR mutated (TMB high: 48 % vs 23 %, p = 0.049). At a median follow-up time of 56.1 months (IQR:38.8-72.0), none of the three outcome variables (OS, RFS, TTR) differed significantly by TMB status (all p-values 5 %). This was also true when adjusting for clinicopathological characteristics.While presence of TP53 mutations and absence of EGFR mutations are associated with high TMB, increased TMB had no significant prognostic impact in patients with resected stage I/II lung adenocarcinoma beyond T and N classification, in both unadjusted and adjusted analyses.
- Published
- 2022
47. MALDI mass spectrometry imaging - Diagnostic pathways and metabolites for renal tumor entities
- Author
-
Erlmeier, Franziska, Sun, Na, Shen, Jian-Ren, Feuchtinger, Annette, Buck, Achim, Prade, Verena M, Kunzke, Thomas, Schraml, Peter, Moch, Holger, Autenrieth, Michael, Weichert, Wilko, Hartmann, Arndt, Walch, Axel, and University of Zurich
- Subjects
10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health - Published
- 2022
48. Long-Term Oncological Efficacy of Retroperitoneoscopic Radical Nephrectomy of Localized Renal Cell Cancer pT1-3 (≤12 cm)
- Author
-
Schmid, Florian A, Bausch, Kathrin, Wettstein, Marian S, Feicke, Antje, Weltzien, Boris, Schmid, Daniel M, Strebel, Räto T, Poyet, Cédric, Rupp, Niels J, Sulser, Tullio, Seifert, Hans Helge, Hermanns, Thomas, University of Zurich, and Hermanns, Thomas
- Subjects
2748 Urology ,10062 Urological Clinic ,Treatment Outcome ,Oncology ,Urology ,10049 Institute of Pathology and Molecular Pathology ,Humans ,Laparoscopy ,610 Medicine & health ,2730 Oncology ,Carcinoma, Renal Cell ,Nephrectomy ,Kidney Neoplasms - Published
- 2022
49. What's new in WHO fifth edition - urinary tract
- Author
-
Compérat, Eva, Amin, Mahul B, Berney, Dan M, Cree, Ian, Menon, Santosh, Moch, Holger, Netto, George J, Rao, Vishal, Raspollini, Maria Rosaria, Rubin, Mark A, Srigley, John R, Tan, Puay Hoon, Tickoo, Satish Kumar, Turajlic, Samra, Tsuzuki, Toyonori, University of Zurich, and Compérat, Eva
- Subjects
2734 Pathology and Forensic Medicine ,10049 Institute of Pathology and Molecular Pathology ,610 Medicine & health ,2722 Histology - Published
- 2022
50. Onkozytäre Tumoren der Niere – neue Differenzialdiagnosen
- Author
-
I. Polifka, Riuko Ohashi, Holger Moch, and University of Zurich
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,10049 Institute of Pathology and Molecular Pathology ,medicine ,610 Medicine & health ,business ,Pathology and Forensic Medicine - Abstract
Das Spektrum der onkozytaren Tumoren der Niere hat sich durch neue Erkenntnisse erweitert. Erstellung einer Ubersicht zur Differenzialdiagnose onkozytarer Tumoren der Niere. Eine Literaturrecherche zu onkozytaren Tumoren der Niere wurde durchgefuhrt und die etablierten Entitaten werden dargestellt. Mogliche Differenzialdiagnosen werden diskutiert. Neben den bereits anerkannten Entitaten der World Health Organisation (WHO) 2016 gibt es neue Erkenntnisse in der Gruppe der bisher nicht eindeutig klassifizierbaren onkozytaren Nierentumoren, bei denen sich Charakteristika in Immunhistochemie und auf molekularer Ebene abzeichnen, die zukunftig eine Etablierung neuer Entitaten anbahnen. Wichtige Differenzialdiagnosen konnen zudem abgegrenzt werden, was eine spezifische Therapie onkozytarer Nierentumoren ermoglicht. Die korrekte Diagnose onkozytarer Nierentumoren ermoglicht nicht nur eine verbesserte Prognoseeinschatzung (und ggf. spezifische Therapieoptionen), sondern ist auch im Hinblick auf eine mogliche Assoziation zu einem Tumordispositionssyndrom klinisch von Bedeutung.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.